Pazopanib-induced fatal heart failure in a patient with unresectable soft tissue sarcoma and review of literature

Basit Öğe Kaydı
dc.contributor.authorKaraagac, Mustafa
dc.contributor.authorEryilmaz, Melek Karakurt
dc.date.accessioned2024-02-23T14:27:00Z
dc.date.available2024-02-23T14:27:00Z
dc.date.issued2020
dc.departmentNEÜen_US
dc.description.abstractIntroduction Pazopanib, an oral multi-targeted tyrosine kinase inhibitor, is associated with improved outcomes in patients with unresectable or metastatic soft tissue sarcoma. Pazopanib may cause cardiotoxicity such as heart failure. Case report A 50-year-old female patient with no cardiovascular risk factors other than the previous treatment with adriamycin had a baseline left ventricular ejection fraction of 60%. She was receiving pazopanib 800 mg once daily for advanced leiomyosarcoma of the presacral area. On the 60th day of treatment, she presented with fatigue, palpitation, and exertional dyspnea for several days. Echocardiography was performed, and left ventricular ejection fraction was measured as 25%. Pazopanib-induced heart failure was considered and all other possible preliminary diagnoses were excluded. Management and outcome Pazopanib was stopped immediately. Bisoprolol fumarate 5 mg orally once daily, spironolactone 100 mg orally once daily, furosemide 40 mg orally once daily, and ramipril 2.5 mg orally once daily were started. The patient's symptoms partially improved. Second echocardiography was performed after 15 days, and left ventricular ejection fraction was measured as 35%. But, despite pazopanib was not resumed and cardiac support treatment was administered, she died four weeks after discontinuation of pazopanib due to heart failure. Discussion Pazopanib-induced heart failure may be fatal. Physicians and patients should be aware of the cardiotoxicity risk when managing the use of pazopanib in soft tissue sarcoma.en_US
dc.identifier.doi10.1177/1078155219875797
dc.identifier.endpage774en_US
dc.identifier.issn1078-1552
dc.identifier.issn1477-092X
dc.identifier.issue3en_US
dc.identifier.pmid31547750en_US
dc.identifier.scopus2-s2.0-85073979946en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage768en_US
dc.identifier.urihttps://doi.org/10.1177/1078155219875797
dc.identifier.urihttps://hdl.handle.net/20.500.12452/14419
dc.identifier.volume26en_US
dc.identifier.wosWOS:000488726300001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofJournal Of Oncology Pharmacy Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectFatalen_US
dc.subjectHeart Failureen_US
dc.subjectPazopaniben_US
dc.subjectSoft Tissue Sarcomaen_US
dc.titlePazopanib-induced fatal heart failure in a patient with unresectable soft tissue sarcoma and review of literatureen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu